|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
US6322789B1
(en)
|
1991-08-26 |
2001-11-27 |
Epimmune, Inc. |
HLA-restricted hepatitis B virus CTL epitopes
|
|
ATE181571T1
(de)
|
1991-09-23 |
1999-07-15 |
Medical Res Council |
Methoden zur herstellung humanisierter antikörper
|
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
|
CA2115811A1
(en)
|
1993-02-17 |
1994-08-18 |
Claus Krebber |
A method for in vivo selection of ligand-binding proteins
|
|
US5635363A
(en)
|
1995-02-28 |
1997-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
|
|
US5869270A
(en)
|
1996-01-31 |
1999-02-09 |
Sunol Molecular Corporation |
Single chain MHC complexes and uses thereof
|
|
US6211342B1
(en)
|
1996-07-18 |
2001-04-03 |
Children's Hospital Medical Center |
Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
|
|
US20050003431A1
(en)
|
1996-08-16 |
2005-01-06 |
Wucherpfennig Kai W. |
Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
|
|
US6218363B1
(en)
|
1996-08-28 |
2001-04-17 |
Thomas Jefferson University |
MHC peptides and methods of use
|
|
JP3816959B2
(ja)
|
1997-02-13 |
2006-08-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
肝細胞癌の予防および処置
|
|
US7098306B2
(en)
|
1997-02-13 |
2006-08-29 |
The Regents Of The University Of California |
Method and compositions for treating hepatocellular cancer
|
|
US6268411B1
(en)
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
|
ATE491465T1
(de)
|
1997-05-08 |
2011-01-15 |
Oncothyreon Inc |
Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
|
|
US20030007978A1
(en)
|
1997-09-16 |
2003-01-09 |
Burrows Gregory G. |
Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
|
|
US6696304B1
(en)
|
1999-02-24 |
2004-02-24 |
Luminex Corporation |
Particulate solid phase immobilized protein quantitation
|
|
EP1173204B1
(en)
|
1999-04-30 |
2010-04-21 |
The Trustees Of The University Of Pennsylvania |
Mutant human cd80 and compositions for and methods of making and using the same
|
|
US20020006664A1
(en)
|
1999-09-17 |
2002-01-17 |
Sabatini David M. |
Arrayed transfection method and uses related thereto
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
CN1430728A
(zh)
|
2000-05-25 |
2003-07-16 |
苏诺尔分子公司 |
T细胞受体交互作用的调节
|
|
US20020122820A1
(en)
|
2001-01-16 |
2002-09-05 |
Hildebrand William H. |
Soluble MHC artificial antigen presenting cells
|
|
US6800748B2
(en)
|
2001-01-25 |
2004-10-05 |
Large Scale Biology Corporation |
Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
|
|
AU2002240818C1
(en)
|
2001-03-14 |
2008-11-06 |
Agilent Technologies, Inc. |
MHC molecule constructs and their uses for diagnosis and therapy
|
|
AU2002309865A1
(en)
|
2001-05-15 |
2002-11-25 |
University Of Medicine & Dentistry Of New Jersey |
Methods for analyzing interactions between proteins in live and intact cells
|
|
US20040161817A1
(en)
|
2001-06-04 |
2004-08-19 |
Corixa Corporation |
Compositions and methods for high-level, large-scale production of recombinant proteins
|
|
US20030017134A1
(en)
|
2001-06-19 |
2003-01-23 |
Technion Research And Development Foundation Ltd. |
Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
|
|
AU2002368044A1
(en)
|
2001-06-22 |
2004-04-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
AU2002322211A1
(en)
|
2001-07-12 |
2003-01-29 |
Canvac |
Methods and compisitions for activation human t cells in vitro
|
|
AU2002363354A1
(en)
|
2001-07-27 |
2003-05-19 |
Human Genome Sciences, Inc. |
Heteromultimeric tnf ligand family members
|
|
BR0214650A
(pt)
*
|
2001-12-04 |
2005-05-03 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
US8895020B2
(en)
|
2002-04-19 |
2014-11-25 |
Washington University |
Single chain trimers and uses therefor
|
|
DE60332358D1
(de)
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
EP1599502A1
(en)
|
2003-02-27 |
2005-11-30 |
TheraVision GmbH |
A molecule which binds cd80 and cd86
|
|
AU2003901876A0
(en)
|
2003-04-17 |
2003-05-08 |
The Macfarlane Burnet Institute For Medical Research And Public Health |
Viral vector
|
|
US20050042641A1
(en)
|
2003-05-27 |
2005-02-24 |
Cold Spring Harbor Laboratory |
In vivo high throughput selection of RNAi probes
|
|
US7696306B2
(en)
|
2003-07-11 |
2010-04-13 |
Board of Agents of the University of Nebraska |
Compositions and methods for preventing or treating cancer
|
|
EP2783699A1
(en)
|
2003-09-05 |
2014-10-01 |
Oregon Health & Science University |
Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
|
|
US7470513B2
(en)
|
2003-11-10 |
2008-12-30 |
Academia Sinica |
Risk assessment for adverse drug reactions
|
|
WO2005091956A2
(en)
|
2004-03-05 |
2005-10-06 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
|
DE102004014983A1
(de)
|
2004-03-26 |
2005-10-20 |
Univ Stuttgart |
Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
|
|
US20060034850A1
(en)
|
2004-05-27 |
2006-02-16 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
CA2523032A1
(en)
|
2005-10-07 |
2007-04-07 |
Immunovaccine Technologies Inc. |
Vaccines for cancer therapy
|
|
KR20080082628A
(ko)
|
2005-11-10 |
2008-09-11 |
리셉터 바이오로직스 인크 |
수용체 및 리간드 이소형태의 제조 방법
|
|
US7943133B2
(en)
|
2006-02-02 |
2011-05-17 |
Boston Biocom Llc |
Mesothelin antibody protein fusions and methods of use
|
|
EP2863222A1
(en)
|
2006-03-06 |
2015-04-22 |
Amunix Operating Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US8518697B2
(en)
|
2006-04-04 |
2013-08-27 |
Washington University |
Single chain trimers and uses therefor
|
|
MX2008014722A
(es)
|
2006-05-19 |
2011-04-15 |
Teva Pharma |
Proteinas de fusion, usos de las mismas y procesos para producir las mismas.
|
|
EP1889851A1
(en)
|
2006-08-18 |
2008-02-20 |
Charite Universitätsmedizin-Berlin |
PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
|
|
US8992937B2
(en)
|
2006-08-28 |
2015-03-31 |
Washington University |
Disulfide trap MHC class I molecules and uses therefor
|
|
NZ601175A
(en)
|
2006-12-28 |
2012-12-21 |
Int Inst Cancer Immunology Inc |
Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
|
|
CN101657213B
(zh)
|
2007-02-15 |
2014-02-26 |
曼康公司 |
用于增强t细胞应答的方法
|
|
WO2008113970A2
(en)
|
2007-03-16 |
2008-09-25 |
Ucl Business Plc |
Peptides
|
|
WO2008116468A2
(en)
|
2007-03-26 |
2008-10-02 |
Dako Denmark A/S |
Mhc peptide complexes and uses thereof in infectious diseases
|
|
EP2615172A1
(en)
|
2007-04-27 |
2013-07-17 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
CN103298935A
(zh)
|
2007-08-15 |
2013-09-11 |
阿穆尼克斯公司 |
用于改善生物活性多肽性能的组合物和方法
|
|
US8926961B2
(en)
|
2007-10-03 |
2015-01-06 |
Board Of Trustees Of The University Of Arkansas |
HPV E6 protein T cell epitopes and uses thereof
|
|
CN101418309B
(zh)
|
2007-10-23 |
2011-05-04 |
中国农业科学院上海兽医研究所 |
柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
TW201008574A
(en)
|
2008-08-19 |
2010-03-01 |
Oncotherapy Science Inc |
INHBB epitope peptides and vaccines containing the same
|
|
WO2010037395A2
(en)
|
2008-10-01 |
2010-04-08 |
Dako Denmark A/S |
Mhc multimers in cancer vaccines and immune monitoring
|
|
EP2184070A1
(en)
|
2008-11-07 |
2010-05-12 |
Hla-G Technologies |
HLA-G proteins and pharmaceutical uses thereof
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
SI2393828T1
(sl)
|
2009-02-03 |
2017-01-31 |
Amunix Operating Inc. |
Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
|
|
EP2445935B1
(en)
|
2009-06-25 |
2015-07-01 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
JP2013538555A
(ja)
|
2010-07-15 |
2013-10-17 |
テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド |
Ｍｈｃクラスｉｉとグルタミン酸デカルボキシラーゼ（ｇａｄ）自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
|
|
EP3851459B1
(en)
|
2010-09-21 |
2024-05-01 |
Altor BioScience, LLC |
Multimeric il-15 soluble fusion molecules and methods of making and using same
|
|
JP6093712B2
(ja)
|
2010-12-22 |
2017-03-08 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン２のスーパーアゴニストおよびアンタゴニスト
|
|
US9266938B2
(en)
*
|
2011-02-10 |
2016-02-23 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
KR102038155B1
(ko)
|
2011-06-22 |
2019-10-29 |
에프. 호프만-라 로슈 아게 |
Mhc 클래스 i 포함 복합체를 사용한 순환 바이러스-특이적 세포독성 t-세포에 의한 표적 세포의 제거
|
|
CN107988156B
(zh)
|
2011-06-30 |
2022-01-04 |
建新公司 |
T细胞活化的抑制剂
|
|
DE112011100879A5
(de)
|
2011-08-30 |
2013-11-14 |
Jacobs University Bremen Ggmbh |
Gen codiert für ein MHC-Klasse-I-Molekül, Plasmid, Expressionssystem, Protein, Multimer, Reagenz und Kit zum Analysieren einer T-Zellen-Frequenz
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
HK1204261A1
(en)
|
2012-01-13 |
2015-11-13 |
Memorial Sloan Kettering Cancer Center |
Immunogenic wt-1 peptides and methods of use thereof
|
|
EP2809345A4
(en)
|
2012-02-03 |
2015-11-25 |
Univ Emory |
IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
BR112015011111A2
(pt)
|
2012-11-30 |
2017-11-14 |
Roche Glycart Ag |
proteína multifuncional e formulação farmacêutica
|
|
JP2016500255A
(ja)
|
2012-12-11 |
2016-01-12 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
ハイスループットなレセプター：リガンド同定の方法
|
|
SG11201504414UA
(en)
|
2012-12-21 |
2015-07-30 |
Hoffmann La Roche |
Disulfide-linked multivalent mhc class i comprising multi-function proteins
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
PT2945647T
(pt)
|
2013-01-15 |
2020-11-26 |
Memorial Sloan Kettering Cancer Center |
Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
|
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
PL3587448T3
(pl)
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
|
DK2982681T3
(en)
|
2013-03-29 |
2018-12-10 |
Sumitomo Dainippon Pharma Co Ltd |
WT1 ANTIGENPEPTIDKONJUGATVACCINE
|
|
WO2014185387A1
(ja)
|
2013-05-13 |
2014-11-20 |
株式会社癌免疫研究所 |
免疫療法の臨床効果の予測法
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
BR112016001114B1
(pt)
|
2013-07-19 |
2023-02-14 |
Vib Vzw |
Composição compreendendo uma proteína de fusão e uso da referida composição
|
|
RS63295B1
(sr)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Anti-vista antitela i fragmenti
|
|
US20170176435A1
(en)
|
2014-01-21 |
2017-06-22 |
Albert Einstein College Of Medicine, Inc. |
Cellular platform for rapid and comprehensive t-cell immunomonitoring
|
|
WO2015130766A1
(en)
|
2014-02-25 |
2015-09-03 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
|
|
KR101804343B1
(ko)
|
2014-02-26 |
2017-12-04 |
텔라 가부시키가이샤 |
Ｗｔ１ 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
JP6652932B2
(ja)
|
2014-06-18 |
2020-02-26 |
アルバート アインシュタイン カレッジ オブ メディシン |
ｓｙｎＴａｃポリペプチド及びその使用
|
|
KR102003754B1
(ko)
|
2014-07-03 |
2019-07-25 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
MX378790B
(es)
|
2014-07-21 |
2025-03-10 |
Delinia Inc |
Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
|
|
CA2957717C
(en)
*
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
JP2017525370A
(ja)
|
2014-08-21 |
2017-09-07 |
ザ ジェネラル ホスピタル コーポレイション |
腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
|
|
WO2016030350A1
(en)
|
2014-08-29 |
2016-03-03 |
F. Hoffmann-La Roche Ag |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
ES2979088T3
(es)
|
2015-03-05 |
2024-09-24 |
Fred Hutchinson Cancer Center |
Proteínas de fusión inmunomoduladoras y usos de las mismas
|
|
CA2980292A1
(en)
|
2015-03-23 |
2016-09-29 |
The Johns Hopkins University |
Hla-restricted epitopes encoded by somatically mutated genes
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
AU2016275312B2
(en)
|
2015-05-06 |
2021-12-23 |
Uti Limited Partnership |
Nanoparticle compositions for sustained therapy
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
US11046745B2
(en)
|
2015-07-14 |
2021-06-29 |
BioNTech SE |
Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof
|
|
CA2993429A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
CN106565836B
(zh)
|
2015-10-10 |
2020-08-18 |
中国科学院广州生物医药与健康研究院 |
高亲和力的可溶性pdl-1分子
|
|
EP4130026A1
(en)
|
2015-11-20 |
2023-02-08 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for treating cancer
|
|
US20190365656A1
(en)
|
2016-01-04 |
2019-12-05 |
Cour Pharmaceuticals Development Company, Inc. |
Particles encapsulating fusion proteins containing linked epitopes
|
|
JP2019511458A
(ja)
|
2016-01-27 |
2019-04-25 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
組み換えＩｇＧ Ｆｃ多量体
|
|
US20190062400A1
(en)
|
2016-03-02 |
2019-02-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR20180132070A
(ko)
|
2016-03-03 |
2018-12-11 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
|
CN109071623B
(zh)
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
US11339201B2
(en)
*
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
JP7071288B2
(ja)
|
2016-05-18 |
2022-05-18 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
EP3538559B1
(en)
|
2016-11-09 |
2025-04-09 |
UTI Limited Partnership |
Recombinant pmhc class ii molecules
|
|
MX2019007611A
(es)
|
2016-12-22 |
2020-07-29 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
|
CN118453840A
(zh)
|
2017-03-15 |
2024-08-09 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
|
US11725210B2
(en)
|
2017-03-17 |
2023-08-15 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
EP3446702A1
(en)
|
2017-08-23 |
2019-02-27 |
Medizinische Hochschule Hannover |
Synthetic vaccine
|
|
WO2019051126A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
AU2018328283A1
(en)
|
2017-09-07 |
2020-02-20 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
BR112020004535A2
(pt)
|
2017-09-07 |
2020-09-08 |
Cue Biopharma, Inc. |
peptídeos moduladores de células t multiméricos e métodos de uso destes
|
|
CA3074839A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
|
|
CN111954679A
(zh)
|
2017-10-03 |
2020-11-17 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019162937A1
(en)
|
2018-02-20 |
2019-08-29 |
Technion Research & Development Foundation Limited |
Immunotherapeutic composition for the treatment of cancer
|
|
WO2020132136A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2020132138A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
TW202039541A
(zh)
|
2018-12-19 |
2020-11-01 |
美商庫爾生物製藥有限公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
JP7691927B2
(ja)
|
2019-03-06 |
2025-06-12 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
|
|
EP3935080A4
(en)
|
2019-03-06 |
2023-04-05 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
WO2020243315A1
(en)
|
2019-05-29 |
2020-12-03 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2020247843A2
(en)
|
2019-06-05 |
2020-12-10 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
|
|
EP3986448A4
(en)
|
2019-06-19 |
2023-07-12 |
Cue Biopharma, Inc. |
MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
WO2021055594A1
(en)
|
2019-09-20 |
2021-03-25 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
CN114423497A
(zh)
|
2019-10-23 |
2022-04-29 |
库尔生物制药有限公司 |
修饰的细胞毒性t细胞及其使用方法
|
|
WO2021081239A1
(en)
|
2019-10-23 |
2021-04-29 |
Cue Biopharma, Inc. |
T-cell modulatory chimeric molecules and methods of use thereof
|
|
AU2020395122A1
(en)
|
2019-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Peptide-MHC II protein constructs and uses thereof
|
|
TW202136317A
(zh)
|
2019-12-20 |
2021-10-01 |
美商再生元醫藥公司 |
新穎之ｉｌ２促效劑及其使用方法（二）
|
|
CN115176015A
(zh)
|
2020-02-28 |
2022-10-11 |
国立大学法人金泽大学 |
免疫调节法、免疫调节用核酸组合物及其用途
|
|
GB202005617D0
(en)
|
2020-04-17 |
2020-06-03 |
Adaptimmune Ltd |
Improved t cell manufacturing process
|
|
TW202208395A
(zh)
|
2020-05-12 |
2022-03-01 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
CN113823723A
(zh)
|
2020-06-18 |
2021-12-21 |
光宝光电(常州)有限公司 |
发光二极管封装结构
|
|
IL299834A
(en)
|
2020-07-14 |
2023-03-01 |
Cue Biopharma Inc |
with binding sites and methods for using them T - cellular modulatory polypeptides
|
|
EP4232071A4
(en)
|
2020-10-23 |
2024-08-28 |
Asher Biotherapeutics, Inc. |
FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
|
|
WO2022125694A1
(en)
|
2020-12-09 |
2022-06-16 |
Asher Biotherapeutics, Inc. |
Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
|
|
CA3201573A1
(en)
|
2020-12-09 |
2022-06-16 |
Ivana DJURETIC |
Targeted cytokine construct for engineered cell therapy
|